Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Researchers at the Gladstone Institute of Neurological Disease and Baylor College of Medicine recently reported the discovery of a mechanism by which the protein, Amyloid-Beta, may impair neurological functions in Alzheimer's disease. The protein, which is known to accumulate in the brains of Alzheimer patients, has long been a focus of research into the causes and treatment of the disease.

During this weeks podcast, Dr. Lennart Mucke, GIND director and senior author of the study, talks about what the research team actually discovered and why the group's finding was surprising. He also discusses the research models used in the study and how they shed light on Alzheimer.s memory loss.

Dr. Mucke provides details on what was learned from the study regarding an association between amyloid-beta protein and seizures in Alzheimer patients, and details the main therapeutic implications of this study for the potential treatment of Alzheimer's disease.

Listen now to this important discussion then return to the blog to give your thoughts on the following question:

Do you believe neurological diseases like Alzheimer's and Parkinson's will become more treatable over the next ten to fifteen years and, if so, why?

Or, if you prefer, post your own topic on the biotech industry subject of your choice. Please share your opinions and observations.

In 1996, Dr. Lennart Mucke, was recruited by Gladstone and the University of California, San Francisco (UCSF) Department of Neurology to head a new program in molecular neurobiology in San Francisco. The rapid progress made by this program resulted in the establishment of the Gladstone Institute of Neurological Disease, which Dr. Mucke has directed since its inauguration in 1998. As director of the Institute, he has developed a vigorous program for research and training in disease-related neuroscience and established close ties with neuroscientists at UCSF. Dr. Mucke has generated valuable transgenic models of Alzheimer’s and Parkinson’s disease and has used them to identify molecular processes that cause or modulate related pathologies and neurological deficits. His contributions have resolved puzzling discrepancies between clinical and pathological findings and provided guidance in the development of novel treatments for these conditions. Dr. Mucke is the first holder of the Joseph B. Martin Distinguished Professorship in Neuroscience at UCSF, where he has joint appointments in the Department of Neurology, the Neuroscience Program, the Biomedical Sciences Program, and the Program in Pharmaceutical Sciences and Pharmacogenomics. He also teaches as a neurology attending at San Francisco General Hospital.

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »